Skip to main content

Advertisement

Table 2 Clinical and parasitological failure by day 14 and day 28

From: Adding artesunate to sulphadoxine-pyrimethamine greatly improves the treatment efficacy in children with uncomplicated falciparum malaria on the coast of Benin, West Africa

  CQ SP SP – AS
DAY 14, n 71 70 77
ACPR 32 (45.1) 46 (65.7) 76 (98.7)
ETF, n (%) 18 (25.4) 16 (22.9) 0 (0.0)
LCF, n (%) 6 (8.5) 2 (2.9) 0 (0.0)
LPF, n (%) 15 (21.1) 6 (8.6) 1 (1.3)
TOTAL FAILURES    
   Per protocol, n (%) 39 (54.9) 24 (34.3) 1 (1.3)
   Intention to Treat, n (%) 47/79 (59.5) 31/77 (40.3) 5/81 (6.2)
DAY 28 (PCR uncorrected), n 71 68 76
ACPR 18 (25.4) 37 (54.4) 68 (89.5)
ETF, n (%) 18 (25.4) 16 (23.5) 0 (0.0)
LCF, n (%) 8 (11.3) 4 (5.9) 1 (1.3)
LPF, n (%) 27 (38.0) 11 (16.2) 7 (9.2)
TOTAL FAILURES    
   Per protocol, n (%) 53 (74.6) 31 (45.6) 8 (10.5)
   Intention to Treat, n (%) 61 (77.2) 40 (51.9) 13 (16.0)
DAY 28 (PCR corrected)    
ACPR 20 (28.2) 38 (55.9) 72 (94.7)
ETF, n (%) 18 (25.4) 16 (23.5) 0 (0.0)
LCF, n (%) 8 (11.3) 4 (5.9) 1 (1.3)
LPF, n (%) 25 (35.2) 10 (14.7) 3 (3.9)
TOTAL FAILURES    
   New infections, n (%) 2 (14.3) 1 (14.3) 4 (57.1)
   Per protocol, n (%) 51 (71.8) 30 (44.1) 4 (5.3)
   Intention to Treat, n (%) 59 (74.7) 39 (50.6) 9 (11.1)
   Kaplan Meier survival analysis (%) 71.8 42.0 5.3